CTI BioPharma Corp. said Monday a late-stage trial of a treatment for the blood cancer non-Hodgkin lymphoma failed to meet its main goals. The Phase III trial evaluating Pixuvri combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of an improvement in progression-free survival, the company said in a statement. “We are disappointed with the outcome of the PIX306 trial and will proceed to conduct a thorough review of clinical data to assess the next steps for the PIXUVRI program,” Chief Executive Adam Craig, MD, PhD said in a statement. The trial involved 312 patients who had relapsed and were not eligible for stem cell transplant. Shares were halted premarket for the news, but have gained 94% in 2018, while the S&P 500 has gained 3%.